Ideas

Combinatorial therapy for brain tumor and oesophageal squamous cell carcinoma:  A therapeutic mix encompassing metformin and navitoclax/ABT263 (MAN) inhibits the expression of Integrin a7 (ITGA7), impairs laminin-induced/FAK-mediated signalling, inhibits the proliferation of glioblastoma and oesophageal squamous cell carcinoma stem cells, suppresses tumor cell migration, reduces metastasis and prolongs survival, via down-regulation of its target gene, 5/February/2019, 6.21 am
Combinatorial therapy for brain tumor and oesophageal squamous cell carcinoma:  A therapeutic mix encompassing metformin and navitoclax/ABT263 (MAN) inhibits the expression of Integrin a7 (ITGA7), impairs laminin-induced/FAK-mediated signalling, inhibits the proliferation of glioblastoma and oesophageal squamous cell carcinoma stem cells, suppresses tumor cell migration, reduces metastasis and prolongs survival, via down-regulation of its target gene, 5/February/2019, 6.21 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from the Institute of General Pathology, Università Cattolica del Sacro Cuore and Fondazione Policlinico Universitario A. Gemelli, 00168 Rome, Italy; Department of Oncology and…

read more

Molecular therapy for Obesity-associated metabolic deficits/abnormalities: Alogliptin (Trade names: Nesina, Vipidia, Kazano, Oseni), , an anti-hyperglycemic drug in the DPP4 inhibitor class, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 5/February/2019, 5.34 am
Molecular therapy for Obesity-associated metabolic deficits/abnormalities: Alogliptin (Trade names: Nesina, Vipidia, Kazano, Oseni), , an anti-hyperglycemic drug in the DPP4 inhibitor class, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 5/February/2019, 5.34 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 3/February/2019, 11.22 pm
Combinatorial therapy for gynecologic cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of HDAC6, acetylates tumor suppressor proteins, activates tumor suppressor function, and stifles the progression of ARID1A-mutated ovarian cancers, via up-regulation of its target gene, 3/February/2019, 11.22 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:  A study from Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA shows that “ARID1A-mutated ovarian cancers depend on HDAC6 activity” This study…

read more

Molecular therapy for safeguarding your heart against cardiac dysfunction: Rebamipide (Trade names: Mucosta, Rebagen, and Rebagit) , a gastrointestinal medication used in the treatment of gastroduodenal ulcers, and gastritis, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 3/February/2019, 11.10 pm
Molecular therapy for safeguarding your heart against cardiac dysfunction: Rebamipide (Trade names: Mucosta, Rebagen, and Rebagit) , a gastrointestinal medication used in the treatment of gastroduodenal ulcers, and gastritis, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 3/February/2019, 11.10 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 3/February/2019, 10.58 pm
Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Metformin and Navitoclax (ABT-263) (MAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 3/February/2019, 10.58 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, Harvard University, Oxford St., Cambridge,…

read more

Ribonucleic acid-based therapy for Diabetes: lncRNA DANCR increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 3/February/2019, 10.50 pm
Ribonucleic acid-based therapy for Diabetes: lncRNA DANCR increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 3/February/2019, 10.50 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham, Birmingham, AL shows that…

read more
Start Typing